An AI-native biotech organization for drug discovery and development. From Target → Molecule → Preclinical → Clinical → BD, coordinated by specialized AI agents.
Virtual Biotech is an open-source project exploring what happens when we move from one AI assistant to an AI-native biotech organization.
Instead of building a single chatbot that answers questions about drug development, Virtual Biotech organizes specialized AI agents into teams that collaborate like a real biotech company.
The traditional biotech model looks like:
Human Scientists
↓
Research Teams
↓
Departments
↓
Program Teams
↓
Drug Candidate
↓
Clinical Development
Virtual Biotech explores a new model:
┌─────────────────────┐
│ AI Chief Scientist│
│ / CSO │
└──────────┬──────────┘
│
┌──────────────────────┼──────────────────────┐
↓ ↓ ↓
┌───────────────┐ ┌───────────────┐ ┌───────────────┐
│ Target & │ │ Discovery & │ │ Clinical & │
│ Biology Team │ │ Molecule Team │ │ Translational │
└───────────────┘ └───────────────┘ └───────────────┘
↓ ↓ ↓
Target ID Molecule Design Clinical Data
Genetics ADME / PK Trial Design
Disease Biology Developability Biomarkers
│ │ │
└──────────────────────┼──────────────────────┘
↓
┌─────────────────────┐
│ Program Management │
│ & Decision Agent │
└──────────┬──────────┘
↓
Drug Pipeline
The goal is not to replace scientists.
The goal is to explore how humans + AI agents can operate a biotech company together.
Virtual Biotech is designed around the complete drug development lifecycle:
Target
↓
Target Validation
↓
Hit / Lead Discovery
↓
Molecule Design
↓
In Silico Evaluation
↓
Preclinical
↓
IND Strategy
↓
Clinical Development
↓
Clinical Data Analysis
↓
Regulatory Strategy
↓
Business Development
Each stage can be handled by specialized agents, tools, and workflows.
Instead of one general-purpose agent, Virtual Biotech uses specialized agents.
Responsible for:
- Defining research strategy
- Prioritizing programs
- Reviewing scientific evidence
- Coordinating research teams
- Challenging assumptions
- Making program-level recommendations
Responsible for:
- Tracking development programs
- Monitoring milestones
- Identifying bottlenecks
- Comparing competing programs
- Maintaining program memory
Analyzes:
- Literature
- Genetics
- Disease biology
- Human datasets
- Competitive pipelines
- Target validation evidence
Evaluates:
- Genetic validation
- Pharmacological validation
- Human evidence
- Biomarker relationships
- Safety liabilities
- Competitive differentiation
Builds disease-mechanism maps and identifies:
- Pathways
- Cell types
- Disease drivers
- Biomarkers
- Resistance mechanisms
Supports:
- Small-molecule discovery
- Structure-based design
- Virtual screening
- Molecular optimization
- SAR analysis
Supports:
- Antibody design
- Bispecific antibodies
- Multispecific antibodies
- Protein engineering
- ADC concepts
Evaluates:
- ADME
- PK
- Solubility
- Stability
- Immunogenicity
- Manufacturability
Agents analyze:
- In vitro studies
- In vivo studies
- PK/PD
- Toxicology
- Biomarkers
- Translational evidence
The objective is to answer:
Is this molecule ready to become a development candidate?
Analyzes:
- ClinicalTrials.gov
- Trial design
- Inclusion / exclusion criteria
- Endpoints
- Patient populations
- Competitor trials
Analyzes:
- ORR
- CR
- PR
- PFS
- OS
- Safety
- Biomarkers
- Subgroup analysis
Supports:
- Phase I strategy
- Phase II design
- Phase III strategy
- Dose selection
- Patient segmentation
- Competitive positioning
Virtual Biotech also treats business development as part of drug development.
Tracks:
- Competitor pipelines
- Clinical milestones
- Trial readouts
- Publications
- Patents
- Financing
- M&A
- Licensing deals
Evaluates:
- Licensing opportunities
- Partnering targets
- Asset valuation
- Strategic fit
- Pipeline gaps
The system is designed around a hierarchical architecture:
Human Scientists
│
↓
┌─────────────────┐
│ AI CSO Agent │
└────────┬────────┘
│
┌────────────────┼────────────────┐
↓ ↓ ↓
Biology Team Discovery Team Clinical Team
│ │ │
┌────┴────┐ ┌────┴────┐ ┌────┴────┐
↓ ↓ ↓ ↓ ↓ ↓
Target Disease Molecule ADME Clinical Data
Agent Agent Agent Agent Agent Agent
│ │ │
└────────────────┼────────────────┘
↓
Evidence / Memory
↓
Decision Engine
↓
Human Review
Virtual Biotech is designed around an evidence-first principle.
Agents should distinguish between:
- Published evidence
- Clinical evidence
- Computational prediction
- Internal analysis
- Hypothesis
- Speculation
Every important conclusion should ideally include:
Claim
↓
Evidence
↓
Source
↓
Confidence
↓
Alternative explanation
The system should never confuse an AI-generated hypothesis with experimental evidence.
Potential data sources include:
- PubMed
- Europe PMC
- bioRxiv
- medRxiv
- ClinicalTrials.gov
- WHO ICTRP
- EU Clinical Trials Information System
- ChEMBL
- DrugBank
- Open Targets
- UniProt
- STRING
- GTEx
- TCGA
- GWAS Catalog
- DepMap
- SEC filings
- Company pipelines
- Investor presentations
- Scientific conferences
- Patents
Agents can access specialized tools rather than relying only on LLM knowledge.
Example:
LLM
│
├── Literature Search
├── Clinical Trial Search
├── PubMed
├── ChEMBL
├── Open Targets
├── ClinicalTrials.gov
├── Molecular Modeling
├── Python / Data Science
├── R
└── Internal Knowledge Base
The architecture is intended to support MCP-compatible tools where appropriate.
A researcher asks:
Should we develop a drug against Target X for pancreatic cancer?
The Virtual Biotech could execute:
CSO Agent
↓
Target Discovery Agent
↓
Disease Biology Agent
↓
Genetics Agent
↓
Clinical Trial Agent
↓
Competitive Intelligence Agent
↓
Safety Agent
↓
Molecule Discovery Agent
↓
Program Strategy Agent
↓
CSO Review
↓
Human Scientist
The final output could contain:
1. Target rationale
2. Human genetic evidence
3. Biological mechanism
4. Existing clinical evidence
5. Competitor landscape
6. Safety considerations
7. Biomarker strategy
8. Potential modalities
9. Development risks
10. Recommended experiments
11. Go / No-Go considerations
The system provides decision support, not autonomous scientific authority.
A potential project structure:
virtual-biotech/
│
├── agents/
│ ├── cso/
│ ├── target/
│ ├── biology/
│ ├── molecule/
│ ├── preclinical/
│ ├── clinical/
│ ├── regulatory/
│ ├── competitive/
│ └── bd/
│
├── tools/
│ ├── literature/
│ ├── clinical_trials/
│ ├── chemistry/
│ ├── genomics/
│ └── analytics/
│
├── workflows/
│ ├── target_validation/
│ ├── drug_discovery/
│ ├── preclinical/
│ └── clinical/
│
├── knowledge/
│ ├── targets/
│ ├── drugs/
│ ├── trials/
│ └── companies/
│
├── memory/
│
├── evaluation/
│
├── configs/
│
├── tests/
│
├── docs/
│
├── examples/
│
└── README.md
The initial implementation can use:
- Python
- LLMs
- LangGraph / agent orchestration
- MCP
- FastAPI
- PostgreSQL
- Vector Database
- Python scientific ecosystem
- Docker
The architecture is intentionally modular so individual components can be replaced.
A Virtual Biotech should not be evaluated only by whether an LLM produces convincing answers.
We should evaluate:
Does the agent correctly interpret the evidence?
Can it find the relevant papers, trials, targets and molecules?
Can it connect evidence across different domains?
Can another researcher reproduce the analysis?
Does the system identify relevant risks and uncertainties?
Would an experienced scientist consider the analysis useful?
Virtual Biotech is not designed to autonomously make irreversible scientific or clinical decisions.
Human experts remain responsible for:
- Scientific judgment
- Experimental validation
- Clinical decisions
- Regulatory decisions
- Patient safety
- Investment decisions
AI agents provide analysis, hypotheses, prioritization and decision support.
The long-term goal is to explore a new paradigm:
What does a biotech company look like when intelligence becomes software?
Today:
1 Scientist
↓
1 Team
↓
1 Department
↓
1 Company
Tomorrow:
Human Scientists
+
AI Agents
↓
AI-Native Teams
↓
AI-Native Departments
↓
AI-Native Biotech
The fundamental question is no longer:
"Can AI discover a drug?"
It becomes:
"Can we build an organization in which humans and AI systematically discover, develop, and evaluate drugs together?"
🚧 Early-stage research project
Current focus:
- Agent architecture
- CSO agent
- Target discovery agent
- Clinical trial intelligence
- Competitive intelligence
- Literature retrieval
- Biomedical knowledge graph
- MCP tool integration
- Multi-agent workflows
- Evaluation framework
- Human-in-the-loop interface
Contributions are welcome.
Areas where contributors can help:
- Agent development
- Biomedical data integration
- Drug discovery workflows
- Clinical development
- MCP tools
- Evaluation
- UI/UX
- Scientific validation
Please open an issue before starting major architectural changes.
Virtual Biotech is an experimental research and software project.
It is intended for research, education, and decision support.
Outputs generated by AI agents should not be treated as medical advice, clinical recommendations, regulatory advice, or validated scientific conclusions without appropriate expert review and experimental validation.
License: TBD
From AI assistant → AI scientist → AI team → AI biotech.
Target → Molecule → Preclinical → Clinical → BD.
Building the operating system for the next generation of biotech.